Insys Therapeutics, Inc. (NASDAQ:INSY) CEO Saeed Motahari bought 5,500 shares of the stock in a transaction on Thursday, August 10th. The stock was purchased at an average cost of $8.92 per share, with a total value of $49,060.00. Following the acquisition, the chief executive officer now owns 15,400 shares in the company, valued at $137,368. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Saeed Motahari also recently made the following trade(s):

  • On Wednesday, June 14th, Saeed Motahari bought 5,400 shares of Insys Therapeutics stock. The stock was purchased at an average cost of $11.10 per share, with a total value of $59,940.00.
  • On Tuesday, May 16th, Saeed Motahari bought 4,500 shares of Insys Therapeutics stock. The stock was purchased at an average cost of $11.98 per share, with a total value of $53,910.00.

Shares of Insys Therapeutics, Inc. (NASDAQ:INSY) traded down 0.11% during midday trading on Thursday, hitting $9.06. The stock had a trading volume of 748,426 shares. The firm’s 50-day moving average price is $12.09 and its 200-day moving average price is $11.45. The stock’s market cap is $658.63 million. Insys Therapeutics, Inc. has a 1-year low of $8.70 and a 1-year high of $18.80.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s revenue was down 38.4% compared to the same quarter last year. Analysts forecast that Insys Therapeutics, Inc. will post ($0.29) earnings per share for the current year.

WARNING: “Insys Therapeutics, Inc. (NASDAQ:INSY) CEO Saeed Motahari Purchases 5,500 Shares” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/insys-therapeutics-inc-nasdaqinsy-ceo-saeed-motahari-purchases-5500-shares.html.

A number of equities analysts have issued reports on the company. Piper Jaffray Companies cut Insys Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $20.00 to $10.00 in a report on Wednesday, May 10th. BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Royal Bank Of Canada lowered their target price on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 4th. Zacks Investment Research cut Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Insys Therapeutics in a report on Friday, June 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $13.25.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 126 shares during the period. Eqis Capital Management Inc. increased its position in Insys Therapeutics by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 66,121 shares of the specialty pharmaceutical company’s stock valued at $836,000 after buying an additional 404 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock valued at $1,012,000 after buying an additional 475 shares in the last quarter. American International Group Inc. increased its position in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in Insys Therapeutics by 4.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 37,885 shares of the specialty pharmaceutical company’s stock valued at $479,000 after buying an additional 1,541 shares in the last quarter. 28.15% of the stock is owned by hedge funds and other institutional investors.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.